Patent Profile: National Tsing Hua University Receives Patent for Method for Early Diagnosis of Liver Cancer

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

National Tsing Hua UniversityLast week, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,628,920, which is entitled "Method for early diagnosis of liver cancer and prediction of metastasis."  The '920 patent, which is assigned to National Tsing Hua University in Taiwan, contains claims to a method of determining the risk of liver cancer and metastasis.

The inventors demonstrated that alpha-mannosidase RNA expression levels, specifically MAN1A1, MAN1A2 and MAN1B1, in liver tissue obtained from hepatitis B virus positive liver cancer patients were approximately double the levels of control liver tissue, with increased RNA expression levels correlating with a more advanced cancer stage.  Interestingly, MAN1C1 RNA expression levels in stage I or II liver cancer patients were approximately half the level than that in normal liver tissue.

A review of the file history of the '920 patent indicates that the Examiner issued a rejection of the claims under 35 U.S.C. § 101 in a non-final Office Action mailed December 4, 2012 for being drawn to a non-statutory method for having a "natural principal" as a limiting step without reciting additional steps that integrate the natural principal into the claimed invention.  The Examiner asserted that the "natural principal" constituted the levels of MAN1A1, MAN1A2, MAN1B1, MAN1C1, and MMP9 in samples from a subject as compared to controls are indicative of risk of liver metastasis.  The Examiner stated that, according to Mayo v. Prometheus, a claim that focuses on use of a natural principal must also include additional elements or steps to show that the inventors have practically applied, and added something significant, to the natural principal itself.

As originally filed, claim 6 of the '920 patent recited:

6.  A method for diagnosis of liver metastasis, comprising the steps of:
    (A)  providing a sample obtained from a subject;
    (B)  assessing the expression level of four subtypes of a-mannosidase genes consisting of MAN1A1, MAN1A2, MAN1B1 and MAN1C1 in the sample;
    (C)  comparing MAN1A1, MAN1A2, MAN1B1 and MAN1C1 expression level in the sample with those in a normal control; and
    (D)  determining whether the subject having a risk of liver metastasis in accordance with the result of step (C);
    wherein while the MAN1A1, MAN1A2 and MAN1B1 expression levels in the sample are higher than those in the normal control, and the MAN1C1 expression level in the sample is lower than that of the normal control, such that the subject is determined to have a risk of liver metastasis.

In response to the § 101 rejection, the Applicant amended claim 6 to add limitations of "specific markers" to detect and assess and compare the expression level by the "specific markers."  Furthermore, the Applicant asserted that claim 6 must be performed using the substantial "specific markers" and thus, the claim amounts to significantly more than a natural principal itself.

In Applicant's response filed on April 8, 2013, claim 6 was amended as follows:

6.  (Currently amended)  A method for diagnosis determining risk of liver metastasis metastatic liver cancer, comprising the steps of:
    (A)  providing a sample obtained from a subject;
    (B)  assessing the RNA expression level of four subtypes of a-mannosidase genes consisting of MAN1A1, MAN1A2, MAN1B1 and MAN1C1 in the sample by detecting with one or a plurality of specific markers;
    (C)  comparing the specific markers of MAN1A1, MAN1A2, MAN1B1 and MAN1C1 expression level in the sample with those in a normal control; and
    (D)  determining whether the subject having has a risk of liver metastasis of liver cancer in accordance with the result of step (C);
    wherein a subject with while the MAN1A1, MAN1A2 and MAN1B1 expression levels in the sample that are higher than those in the normal control, and [[the]] MAN1C1 expression level in the sample that is lower than that of the normal control, such that the subject is determined to have indicates the subject has a high risk of liver metastasis of liver cancer,
    wherein the sample and the normal control are liver biopsy or blood sample.

In the next and final Office Action mailed May 29, 2013, the Examiner withdrew the § 101 rejection without comment, but issued a rejection under 35 U.S.C. § 112, second paragraph, for the unclear recitation of "markers" in claim 6.  In order to expedite prosecution, the Examiner proposed amendments to claim 6 that removed the "specific markers" amendment made by the Applicant.  In a response to the final Office Action filed in August of 2013, the Applicant amended claim 6 (which issued as claim 1 in the '920 patent) to include the Examiner's recommended amendment to remove the recitation of "specific markers."  The application was allowed in September.

Claim 1 of the '920 patent recites:

Claim 1.  A method for determining risk of metastatic liver cancer, comprising the steps of:
    (A)  providing a sample obtained from a subject;
    (B)  assessing the RNA expression level of four subtypes of alpha-mannosidase genes consisting of MAN1A1, MAN1A2, MAN1B1 and MAN1C1 in the sample by detecting MAN1A1, MAN1A2, MAN1B1 and MAN1C1 RNA expression levels in the sample;
    (C)  comparing the MAN1A1, MAN1A2, MAN1B1 and MAN1C1 expression levels in the sample with MAN1A1, MAN1A2, MAN1B1 and MAN1C1 expression levels in a normal control; and
    (D)  determining whether the subject has a risk of metastasis of liver cancer in accordance with the result of step (C);
    wherein a subject with MAN1A1, MAN1A2 and MAN1B1 expression levels in the sample that are higher than those in the normal control, and MAN1C1 expression level in the sample that is lower than that of the normal control has a high risk of metastasis of liver cancer, wherein the sample and the normal control are liver biopsies.

 

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.